Morgan Stanley Arcutis Biotherapeutics, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 3,838,541 shares of ARQT stock, worth $54.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,838,541

Previous 4,243,911 9.55%

Holding current value

$54.3 Million

Previous $59.1 Million 1.55%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$11.4 - $17.29 $4.62 Million - $7.01 Million	-405,370 Reduced 9.55%	3,838,541 $60 Million
Q4 2024 Feb 14, 2025	BUY	$8.31 - $14.99 $3.85 Million - $6.94 Million	462,716 Added 12.24%	4,243,911 $59.1 Million
Q3 2024 May 14, 2025	SELL	$8.32 - $11.0 $1.59 Million - $2.11 Million	-191,499 Reduced 4.82%	3,781,195 $35.2 Million
Q3 2024 Nov 14, 2024	SELL	$8.32 - $11.0 $1.59 Million - $2.11 Million	-191,499 Reduced 4.82%	3,781,195 $35.2 Million
Q2 2024 May 14, 2025	SELL	$7.24 - $12.53 $1.96 Million - $3.4 Million	-271,217 Reduced 6.39%	3,972,694 $36.9 Million
Q2 2024 Oct 17, 2024	SELL	$7.24 - $12.53 $243,560 - $421,521	-33,641 Reduced 0.84%	3,972,694 $36.9 Million
Q2 2024 Aug 14, 2024	SELL	$7.24 - $12.53 $243,560 - $421,521	-33,641 Reduced 0.84%	3,972,694 $36.9 Million
Q1 2024 Oct 17, 2024	BUY	$3.25 - $11.77 $109,333 - $395,954	33,641 Added 0.85%	4,006,335 $39.7 Million
Q1 2024 Aug 16, 2024	SELL	$3.25 - $11.77 $6.75 Million - $24.4 Million	-2,076,737 Reduced 34.14%	4,006,335 $39.7 Million
Q1 2024 May 15, 2024	SELL	$3.25 - $11.77 $6.75 Million - $24.4 Million	-2,076,737 Reduced 34.14%	4,006,335 $39.7 Million
Q4 2023 Aug 16, 2024	BUY	$1.84 - $4.82 $3.88 Million - $10.2 Million	2,110,378 Added 53.12%	6,083,072 $19.6 Million
Q4 2023 Feb 13, 2024	BUY	$1.84 - $4.82 $10.8 Million - $28.3 Million	5,861,032 Added 2639.63%	6,083,072 $19.6 Million
Q3 2023 Nov 15, 2023	SELL	$5.31 - $10.98 $1.4 Million - $2.9 Million	-263,938 Reduced 54.31%	222,040 $1.18 Million
Q2 2023 Aug 14, 2023	BUY	$7.51 - $15.0 $1.11 Million - $2.22 Million	148,324 Added 43.93%	485,978 $4.63 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $17.14 $1.43 Million - $2.39 Million	139,590 Added 70.48%	337,654 $3.71 Million
Q4 2022 Feb 14, 2023	BUY	$13.96 - $20.4 $1.02 Million - $1.49 Million	73,138 Added 58.55%	198,064 $2.93 Million
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $299,112 - $451,601	16,757 Added 15.49%	124,926 $2.39 Million
Q2 2022 Oct 27, 2022	BUY	$16.33 - $22.2 $175,008 - $237,917	10,717 Added 11.0%	108,169 $2.3 Million
Q2 2022 Aug 15, 2022	BUY	$16.33 - $22.2 $175,008 - $237,917	10,717 Added 11.0%	108,169 $2.3 Million
Q1 2022 Oct 27, 2022	SELL	$14.38 - $22.79 $154,110 - $244,240	-10,717 Reduced 9.91%	97,452 $1.88 Million
Q1 2022 May 13, 2022	BUY	$14.38 - $22.79 $638,946 - $1.01 Million	44,433 Added 83.81%	97,452 $1.88 Million
Q4 2021 Feb 14, 2022	SELL	$14.98 - $25.5 $1.36 Million - $2.31 Million	-90,727 Reduced 63.12%	53,019 $1.1 Million
Q3 2021 Nov 15, 2021	BUY	$19.28 - $27.1 $2.77 Million - $3.9 Million	143,746 New	143,746 $3.43 Million

Others Institutions Holding ARQT

# of Institutions

250

Shares Held

126M

Call Options Held

605K

Put Options Held

170K

View Full List

About Arcutis Biotherapeutics, Inc.

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $851M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

More about ARQT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account